EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)

NCT02635386 on ClinicalTrials.gov · last registry update 2021-01-29

A small phase 3 — 119 participants, against a typical 424. The sponsor logged completion for 22 July 2020. Primary outcome, as filed: Oral Disposition (Insulin Sensitivity-insulin Secretion) Index. exenatide is approved in the US, but not for obesity and pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Woman's
Sponsor type: Other
Enrollment: 119
Started: 2016-03-22
Primary completion: 2020-07-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Oral Disposition (Insulin Sensitivity-insulin Secretion) Index

Conditions studied

Polycystic Ovary Syndrome · Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.